JOHN BALLANTYNE, FORMER BIOTECHNOLOGY EXECUTIVE, JOINS THE GLUCOTRACK BOARD OF DIRECTORS
GlucoTrack, Inc. (GCTK)
Company Research
Source: GlobeNewswire
Biotech veteran joins Glucotrack’s Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes Rutherford, NJ, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the appointment of John Ballantyne, PhD to its Board of Directors, effective immediately. “We are pleased to welcome John, who has been a long-standing supporter of the Company, to our Board of Directors," said Paul Goode, PhD, President and CEO of Glucotrack. "An entrepreneur himself, John brings extensive experience in driving healthcare research and innovation, strategic growth, and other key business functions that will be invaluable as we continue to expand our organization and move towards commercializing our novel technology." Mr. Ballantyne brings over 20 years of experience
Show less
Read more
Impact Snapshot
Event Time:
GCTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GCTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GCTK alerts
High impacting GlucoTrack, Inc. news events
Weekly update
A roundup of the hottest topics
GCTK
News
- GLUCOTRACK ANNOUNCES NEW VICE PRESIDENT OF CLINICAL OPERATIONSGlobeNewswire
- Glucotrack’s Innovative Blood Glucose Monitoring Concept Resonates with Patients with Diabetes, According to New Survey Presented at Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual ConferenceGlobeNewswire
- GLUCOTRACK ANNOUNCES POSTER PRESENTATION ON CONTINUOUS BLOOD GLUCOSE MONITOR SURVEY DATA AT THE ASSOCIATION OF DIABETES CARE AND EDUCATION SPECIALISTS (ADCES) 2024 ANNUAL CONFERENCE [Yahoo! Finance]Yahoo! Finance
- GLUCOTRACK ANNOUNCES POSTER PRESENTATION ON CONTINUOUS BLOOD GLUCOSE MONITOR SURVEY DATA AT THE ASSOCIATION OF DIABETES CARE AND EDUCATION SPECIALISTS (ADCES) 2024 ANNUAL CONFERENCEGlobeNewswire
- GLUCOTRACK ANNOUNCES NEW FUNDING FOR DEVELOPMENT OF ITS CONTINUOUS BLOOD GLUCOSE MONITOR [Yahoo! Finance]Yahoo! Finance
GCTK
Sec Filings
- 9/26/24 - Form 8-K
- 9/23/24 - Form S-3
- 9/16/24 - Form S-1
- GCTK's page on the SEC website